Glaucoma News and Research

Latest Glaucoma News and Research

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

Inotek Pharmaceuticals Corp., a leader in the development of innovative medicines to address significant diseases of the eye, today announced that the Company has successfully completed the first two of three stages of a multiple-dose Phase 2b clinical trial of its novel eye-drop candidate, INO-8875, in patients with glaucoma or ocular hypertension.

22 Jul 2011

U.S. physicians to receive nearly $10M from Humana's Provider Quality Rewards Program

Humana Inc. has begun distributing nearly $10 million to physicians across the U.S. who participate in Humana's Provider Quality Rewards Program. Approximately 2,800 physician practices will receive payments of as much as $175,000 in recognition of performance improvements their practices made during 2010 related to improved outcomes for Humana's Medicare members.

21 Jul 2011

Retinal cells require vitamin C to function properly

Nerve cells in the eye require vitamin C in order to function properly - a surprising discovery that may mean vitamin C is required elsewhere in the brain for its proper functioning, according to a study by scientists at Oregon Health & Science University recently published in the Journal of Neuroscience.

16 Jul 2011

Study: Overall awareness about eye health lower among ethnic Americans

The results of recent, comprehensive research supported by Transitions Optical revealed that the majority of Americans are not taking the proper steps to care for the health of their eyes, and that awareness of both short- and long-term effects of UV exposure on vision is remarkably low.

15 Jul 2011

African-Americans with glaucoma have higher oxygen levels than Caucasians

Measuring oxygen during eye surgery, investigators at Washington University School of Medicine in St. Louis have discovered a reason that may explain why African-Americans have a higher risk of glaucoma than Caucasians.

12 Jul 2011

AHAF awards 22 new grants to scientists worldwide for innovative vision research

The American Health Assistance Foundation (AHAF), a nonprofit organization with a history of funding cutting-edge research on age-related diseases, announced today that it has awarded 22 new grants totaling nearly $2.2 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible vision loss and blindness in the U.S.

8 Jul 2011

Healthy diet might help reduce risk of macular degeneration

Eating a diet high in vitamin D, as well as the nutrients betaine and methionine, might help reduce the risk of macular degeneration, according to new research conducted by Tufts Medical Center scientists. Their study of identical twins from the US World War II Twin Registry also found that the more a person smoked, the higher their risk of developing macular degeneration.

6 Jul 2011

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Scil Proteins, a private biopharmaceutical company specialized in the research, development and production of recombinant proteins, today announced that it has signed an agreement with Anabasis Pharma.

30 Jun 2011

STSI joins JAX consortium to develop targeted cancer therapies

The Scripps Translational Science Institute (STSI) of San Diego, Calif., has joined a national consortium of research institutions headed by The Jackson Laboratory (JAX) that is building a library of primary human tumors with the goal of developing highly targeted cancer therapies.

30 Jun 2011

Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen Pharmaceuticals Inc. today announced positive top line data from the Phase II clinical trial of MIM-D3 for dry eye disease. The trial demonstrated statistically significant improvements in signs and symptoms with its low (1%) and high (5%) doses of MIM-D3, together with excellent safety and tolerability profiles.

27 Jun 2011

Ivantis receives $17 MM NEA, Delphi Ventures funds to expand Hydrus device clinical activities

Ivantis announced today at the World Glaucoma Congress in Paris that it has received $17 MM in funding from New Enterprise Associates (NEA) and Delphi Ventures.

27 Jun 2011

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

A side effect of many commonly used drugs appears to increase the risks of both cognitive impairment and death in older people, according to new research led by the University of East Anglia.

24 Jun 2011

New VEP technique fast and effective for detecting glaucoma damage

A recent paper published in the Journal of Glaucoma shows a new visual evoked potential (VEP) technique to be a fast, objective method to screen for functional damage in glaucomatous eyes.

22 Jun 2011

Functional vision restored after 55 years

After being hit in the eye by a stone, a detached retina left a man blind in his right eye. Despite surgery to remove a cataract when the man was 23, which temporarily restored light perception, the patient was completely blind in that eye.

17 Jun 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.

16 Jun 2011

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Drug delivery company pSivida Corp today announced it amended and restated its Research and Development Agreement with Pfizer Inc. to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.

15 Jun 2011

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Cypress Pharmaceutical announced today that the Food and Drug Administration (FDA) approved a new drug application (NDA) for ZUTRIPRO Oral Solution (CIII) and REZIRA Oral Solution.

14 Jun 2011

Schepens, Mass. Eye and Ear to create world's largest ophthalmology research center

The Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute announced today that they are combining forces to create the world's largest and most robust basic and clinical ophthalmology research enterprise with full spectrum bench-to-bedside research that will translate more quickly into better treatment for blinding diseases and ultimately cures.

10 Jun 2011

Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa

Somaxon Pharmaceuticals, Inc. and Paladin Labs Inc. today announced that they have entered into an exclusive collaboration under which Paladin will commercialize Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance in Canada, South America and Africa.

8 Jun 2011

New Westchester Montefiore Laser and Eye Center to offer ophthalmology services

The new Montefiore Laser and Eye Center recently opened its doors to provide comprehensive care to Westchester patients at the Montefiore Medical Specialists of Westchester in Scarsdale, New York. Seven board-certified ophthalmologists from the Department of Ophthalmology and Visual Sciences at Montefiore Medical Center provide patients with specialty emphasis in pediatric ophthalmology, oculoplastic surgery, glaucoma, cornea and laser refractive surgery.

8 Jun 2011

Glaucoma News and Research

Latest Glaucoma News and Research

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

U.S. physicians to receive nearly $10M from Humana's Provider Quality Rewards Program

Retinal cells require vitamin C to function properly

Study: Overall awareness about eye health lower among ethnic Americans

African-Americans with glaucoma have higher oxygen levels than Caucasians

AHAF awards 22 new grants to scientists worldwide for innovative vision research

Healthy diet might help reduce risk of macular degeneration

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

STSI joins JAX consortium to develop targeted cancer therapies

Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

Ivantis receives $17 MM NEA, Delphi Ventures funds to expand Hydrus device clinical activities

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

New VEP technique fast and effective for detecting glaucoma damage

Functional vision restored after 55 years

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Schepens, Mass. Eye and Ear to create world's largest ophthalmology research center

Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa

New Westchester Montefiore Laser and Eye Center to offer ophthalmology services

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in